In vitro efficacy of various antibiotic combinations against Pseudomonas aeruginosa isolates

被引:8
作者
Nazli, Ebru [1 ]
Zer, Yasemin [1 ]
Eksi, Fahriye [1 ]
机构
[1] Gaziantep Univ, Fac Med, Dept Microbiol & Clin Microbiol, TR-27100 Sahinbey, Gaziantep, Turkey
关键词
Pseudomonas aeruginosa; Epsilometer test; synergy tests; RESISTANT STRAINS; CIPROFLOXACIN; MEROPENEM; LEVOFLOXACIN; EPIDEMIOLOGY; INFECTIONS; COLISTIN; AMIKACIN; IMIPENEM; SYNERGY;
D O I
10.1177/0300060514553490
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Objective: Pseudomonas aeruginosa is one of the leading causes of nosocomial infection. The present study tested the in vitro efficacy of ceftazidime or imipenem combined with amikacin, levofloxacin and colistin in P. aeruginosa isolates. Methods: P. aeruginosa strains, isolated from clinical samples, were assessed for antibiotic susceptibility using the disc diffusion method. Antibiotic combination tests were performed using minimum inhibitory concentration (MIC) test strips and the sum of the Fractional Inhibitory Concentration (Sigma FIC) index was used to assess synergy. Results: Out of 60 isolated P. aeruginosa strains, 100% were susceptible to colistin and 26.7% (16 strains) were multidrug resistant. MIC50 and MIC90 values were 2 and 32 mu g/ml for imipenem; 1.5 and 24 mu g/ml for ceftazidime; 3 and 8 mu g/ml for amikacin; 0.38 and 32 mu g/ml for levofloxacin; 1 and 1.5 mu g/ml for colistin, respectively. Antagonism was not found in any of the antibiotic combinations tested. The amikacin-ceftazidime combination was found to have a synergistic effect in 15% of the strains, but no synergistic effect was detected for other combinations. Conclusions: In Pseudomonas infection, alternative treatment options using different antibiotic combinations should be tested in vitro and findings should be confirmed by clinical studies.
引用
收藏
页码:217 / 225
页数:9
相关论文
共 29 条
  • [1] [Anonymous], 2008, TURK MIKROBIYOL CEM
  • [2] [Anonymous], 2010, T RK MIKROBIYOL CEM
  • [3] Activity of piperacillin/tazobactam in combination with amikacin, ciprofloxacin, and trovafloxacin against Pseudomonas aeruginosa by time-kill
    Burgess, DS
    Hastings, RW
    [J]. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2000, 38 (01) : 37 - 41
  • [4] Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia
    Chamot, E
    El Amari, EB
    Rohner, P
    Van Delden, C
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (09) : 2756 - 2764
  • [5] Chander A., 2013, ASIAN J PHARM CLIN R, V6, P235
  • [6] Clinical and Laboratory Standards Institute, 2012, M100S22 CLIN LAB S S, V32
  • [7] Persistence of microbial communities including Pseudomonas aeruginosa in a hospital environment: a potential health hazard
    de Abreu, Pedro Miguel
    Farias, Pedro Geadas
    Paiva, Gabriel Silva
    Almeida, Ana Maria
    Morais, Paula Vasconcelos
    [J]. BMC MICROBIOLOGY, 2014, 14
  • [8] Activity of levofloxacin and ciprofloxacin in combination with cefepime, ceftazidime, imipenem, piperacillin-tazobactam and amikacin against different Pseudomonas aeruginosa phenotypes and Acinetobacter spp.
    Drago, L
    De Vecchi, E
    Nicola, L
    Colombo, A
    Guerra, A
    Gismondo, MR
    [J]. CHEMOTHERAPY, 2004, 50 (04) : 202 - 210
  • [9] The epidemiology, pathogenesis and treatment of Pseudomonas aeruginosa infections
    Driscoll, James A.
    Brody, Steven L.
    Kollef, Marin H.
    [J]. DRUGS, 2007, 67 (03) : 351 - 368
  • [10] In-Vitro Efficacy of Synergistic Antibiotic Combinations in Multidrug Resistant Pseudomonas Aeruginosa Strains
    Dundar, Devrim
    Otkun, Metin
    [J]. YONSEI MEDICAL JOURNAL, 2010, 51 (01) : 111 - 116